AZD 4144
Alternative Names: AZD-4144Latest Information Update: 14 Aug 2024
At a glance
- Originator AstraZeneca
- Class Anti-inflammatories; Cardiovascular therapies; Small molecules; Urologics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cardiovascular disorders; Kidney disorders
Most Recent Events
- 15 Jul 2024 AstraZeneca initiates enrolment in a phase I trial (In volunteers) in USA (IV, Infusion) (NCT06491550)
- 09 Jul 2024 AstraZeneca plans a phase I trial for Healthy volunteers in USA (IV, Infusion) (NCT06491550)
- 20 Feb 2024 Phase-I clinical trials in Cardiovascular disorders in United Kingdom (PO), prior to February 2024 (AstraZeneca pipeline, February 2024)